programs

Inhibiteurs des PARP pour le traitement du cancer épithélial de l’ovaire et des trompes de Fallope

Présenté par Dre Diane Provencher, Professeure titulaire d’obstétrique-gynécologie, Université de Montréal et Directrice – Recherche en cancer de l’ovaire, Institut du cancer de Montréal.

PARP Inhibitors for Epithelial Ovarian Cancer

Dr. Alon Altman summarizes the Canadian consensus paper on first-line PARPi maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.

RevealingNewDataIn_BC_May20_22.pptx

HER2+ Metastatic Breast Cancer Paper: Canadian Perspective Program

Program summarizing the Canadian perspective paper on a new treatment algorithm for HER2+ Breast Cancer.

RevealingNewDataIn_BC_May20_22_FR.pptx

Traitement du cancer du sein HER2-positif de stade avencé

Programme sur la tratement du cancer du sein HER2-positif.

MBC AE Nursing Program_April27_21.pptx

HER2+ Metastatic Breast Cancer: Management of Adverse Events

Nursing program on managing AEs with ADCs and TKIs. Funding provided by AstraZeneca.

RWE Education program_FINAL_Dec5-19_FINAL.pptx

Real-World Evidence in Inflammatory Arthritis

Program highlighting real-world evidence in inflammatory arthritis.

SCNursingProgram_Jan27_17.pptx

SC Rituximab Nursing Program

**Funding for our medical education programs provided by AstraZeneca and Janssen

Tel. 416-434-8923

Email. info@impactmedicom.com